Here's why the CSL (ASX:CSL) share price is up 5% in a month

Here's two happenings that might explain CSL's recent gains.

| More on:
doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The last 30 days have been good to the CSL Limited (ASX: CSL) share price.

Its gained 4.97% over the month to today, despite releasing no news to the market. In fact, the last time the ASX heard price-sensitive news from CSL was back in early May.

Right now, the CSL share price is $292.73.

Let's take a look at what's been driving it lately.

What's up with the CSL share price?

It's been a quiet, yet productive month on the ASX for CSL.

While it has been in and out of the news due to its contract to produce AstraZeneca's COVID-19 vaccine, the company itself hasn't announced anything.

So, it's a mystery as to why the CSL share price is gaining. Or is it? Here are two happenings that might explain why the healthcare giant's stock is surging.

Australian dollar

CSL is an Australian company, but most of its profit comes from overseas.

In financial year 2020, only 1.5% of CSL's external operating revenue came from Australia.

Most of its income came from the United States. And right now, $1 Australian is only getting US$0.73.

That means when CSL earns income in US dollars, it gets more Aussie bucks back in its pocket. Although, the company does report in US dollars, so we likely won't see the impact of the currency fluctuation in its upcoming full year report.

mRNA possibility

It's also less than a month since the federal government's approach to the market, calling for companies to submit their interest in creating mRNA vaccines, closed to new applicants.

According to reporting by ABC News, Industry Minister Christian Porter confirmed CSL has put itself forward to be considered as an mRNA vaccine manufacturer.

The anticipation of finding out who has won the federal government's favour might also be boosting the CSL share price.

Of course, CSL already makes the AstraZeneca vaccine in its Melbourne facility.

CSL share price snapshot

The month that's been has added to CSL's strong performance on the ASX.

The CSL share price is currently 2% higher than it was at the start of 2021. It has also gained 3% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »

A man packs up a box of belongings at his desk as he prepares to leave the office.
Healthcare Shares

Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Telix shares storm higher on big US and China news

Let's see why this biotech is getting attention on Monday.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

Clinical trial of potential diabetes and arthritis treatment delivers positive results

This drug developer has reported positive results from a phase one trial.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Blue Chip Shares

Is now the time to buy Pro Medicus shares?

After a 13% pullback, Pro Medicus shares are back in focus. Is this weakness an opportunity?

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Where will CSL shares be in 5 years?

Would it be a good time to buy and hold this fallen giant? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »